A Case of Bronchial Wall Angiosarcoma with Complete Response to Pazopanib

Angiosarcomas are a rare subtype of sarcoma, which are mesenchymal derived tumors. Specifically, these malignant and highly aggressive tumors arise from endothelial-cell vascular or lymphatic origin. Because of their rapid clinical course, treatment is often challenging and the prognosis remains poor. As vascular derived neoplasms, angiosarcomas typically express endothelial markers such as vascular endothelial growth factor (VEGF), an observation that has stimulated an interest in using therapeutic agents that targets angiogenic pathways in this rare disease. We present a case of angiosarcoma originating in the lumen of the right main bronchus that was successfully treated with a multi-targeted receptor tyrosine kinase inhibitor Pazopanib after failing first line chemotherapy.